• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Landos Biopharma Inc. (Amendment)

    2/14/24 4:01:28 PM ET
    $LABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LABP alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Landos Biopharma, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    515069102

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 515069102 13G/A Page 2 of 5 Pages

     

    1.

    NAMES OF REPORTING PERSONS

     

    Josep Bassaganya-Riera

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a) ☐

    (b) ☐

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5.  

    SOLE VOTING POWER

     

    0

      6.  

    SHARED VOTING POWER

     

    0

      7.  

    SOLE DISPOSITIVE POWER

     

    0

      8.  

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

     

     

     

    CUSIP No. 515069102 13G/A Page 3 of 5 Pages

     

    Item 1.

     

      (a) Name of Issuer
         
        Landos Biopharma, Inc.
         
      (b) Address of Issuer’s Principal Executive Offices
         
        P.O. Box 11239, Blacksburg VA 24062

     

    Item 2.

     

      (a) Name of Person Filing
         
        Josep Bassaganya-Riera
         
      (b) Address of the Principal Office or, if none, residence
         
        1013 Mcbryde Lane, Blacksburg VA 24060
         
      (c) Citizenship
         
        USA
         
      (d) Title of Class of Securities
         
        Common Stock
         
      (e) CUSIP Number
         
        515069102

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    N/A

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned: 0
           
      (b) Percent of class: 0%
           
      (c) Number of shares as to which the person has:
           
        (i) Sole power to vote or to direct the vote 0
           
        (ii) Shared power to vote or to direct the vote 0
           
        (iii) Sole power to dispose or to direct the disposition of 0
           
        (iv) Shared power to dispose or to direct the disposition of 0

     

     

     

     

    CUSIP No. 515069102 13G/A Page 4 of 5 Pages

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    N/A

     

    Item 8. Identification and Classification of Members of the Group.

     

    N/A

     

    Item 9. Notice of Dissolution of Group.

     

    N/A

     

    Item 10. Certification.

     

    N/A

     

     

     

     

    CUSIP No. 515069102 13G/A Page 5 of 5 Pages

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    02/14/2024

      Date
       
     

    /s/ Josep Bassaganya-Riera

      Signature
       
     

    Josep Bassaganya-Riera

      Name/Title

     

     

    Get the next $LABP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LABP

    DatePrice TargetRatingAnalyst
    4/12/2022$30.00 → $1.40Buy → Hold
    Jefferies
    1/3/2022$15.00 → $7.00Neutral
    JP Morgan
    11/16/2021$20.00 → $16.00Outperform → Market Perform
    SVB Leerink
    10/20/2021$45.00Buy
    Craig-Hallum
    10/19/2021$50.00Buy
    HC Wainwright & Co.
    9/23/2021$39.00Buy
    JonesTrading
    7/30/2021$33.00 → $35.00Outperform
    Raymond James
    More analyst ratings

    $LABP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Landos Biopharma Inc. (Amendment)

      SC 13D/A - Landos Biopharma, Inc. (0001785345) (Subject)

      4/10/24 4:50:56 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Landos Biopharma Inc. (Amendment)

      SC 13D/A - Landos Biopharma, Inc. (0001785345) (Subject)

      4/10/24 4:50:26 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Landos Biopharma Inc. (Amendment)

      SC 13G/A - Landos Biopharma, Inc. (0001785345) (Subject)

      2/14/24 4:01:28 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LABP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Callori Fred

      4 - Landos Biopharma, Inc. (0001785345) (Issuer)

      5/23/24 5:45:25 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mayleben Timothy M

      4 - Landos Biopharma, Inc. (0001785345) (Issuer)

      5/23/24 5:45:33 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Girao Tiago

      4 - Landos Biopharma, Inc. (0001785345) (Issuer)

      5/23/24 5:45:32 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LABP
    SEC Filings

    See more
    • SEC Form 15-12G filed by Landos Biopharma Inc.

      15-12G - Landos Biopharma, Inc. (0001785345) (Filer)

      6/3/24 6:04:57 AM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form RW filed by Landos Biopharma Inc.

      RW - Landos Biopharma, Inc. (0001785345) (Filer)

      5/23/24 4:52:59 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Landos Biopharma Inc.

      S-8 POS - Landos Biopharma, Inc. (0001785345) (Filer)

      5/23/24 4:49:28 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LABP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Landos Biopharma downgraded by Jefferies with a new price target

      Jefferies downgraded Landos Biopharma from Buy to Hold and set a new price target of $1.40 from $30.00 previously

      4/12/22 7:27:34 AM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan reiterated coverage on Landos Biopharma with a new price target

      JP Morgan reiterated coverage of Landos Biopharma with a rating of Neutral and set a new price target of $7.00 from $15.00 previously

      1/3/22 11:17:54 AM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Landos Biopharma downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Landos Biopharma from Outperform to Market Perform and set a new price target of $16.00 from $20.00 previously

      11/16/21 7:18:20 AM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LABP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AbbVie Completes Acquisition of Landos Biopharma

      -   Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD) NORTH CHICAGO, Ill., May 23, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ:LABP). With the completion of the acquisition, Landos is now part of AbbVie. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family), which is currently in Phase 2 for the treatment of moderate to severe UC (NEXUS study; NCT05785715). NLRX1 regulates immunometabolism and inflammation,

      5/23/24 4:05:00 PM ET
      $ABBV
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie

      MILWAUKEE, April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ:LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you. In the transaction, Landos shareholders will receive only $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right

      4/16/24 3:32:00 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

      Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC)NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates

      3/25/24 8:31:00 AM ET
      $ABBV
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LABP
    Leadership Updates

    Live Leadership Updates

    See more
    • Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie

      MILWAUKEE, April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ:LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/landos-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you. In the transaction, Landos shareholders will receive only $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right

      4/16/24 3:32:00 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results

      Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2023. "We continued to advance and execute the NX-13 Phase 2 clinical program (NEXUS) during the second quarter. We have activated sites in the US and are actively recruiting and screening pa

      8/9/23 8:00:00 AM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.

      NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee. "Dr. Batycky is an accomplished biopharmaceutical executive and an important addition to Landos' Board," said Gregory Oakes, President and CEO of Landos. "Dr. Batycky has a proven track record, and we look forward to her contributions as we execute upon our focused strategy in immunology." Dr. Batycky brings with her over 25 years of global drug development experience in the biopharmaceutical in

      5/30/23 4:15:00 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LABP
    Financials

    Live finance-specific insights

    See more
    • Landos Biopharma Provides Comprehensive Update on Clinical Development Plans

      Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future; Significant Optionality for Omilancor, LABP-104 and Four Promising Pre-Clinical Programs Secures Additional $16.7 Million Investment Disciplined Financial Approach Expected to Maintain Cash Runway into First Half of 2025 Company to Host Investor Call at 8:00 AM ET NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP) ("Landos" or the "Company"), a clinical

      1/5/23 7:05:53 AM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

      Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development Plans for Omilancor to Generate Additional Phase 2b Data Prior to Initiating Pivotal Phase 3 Program Determining Optimal Enrollment for Phase 2 Clinical Study of Omilancor in Crohn's Disease and Phase 1b Study of NX-13 in UC Initiated Dosing for LABP-104 in Healthy Volunteers in October 2021 with Results Expected in 1H 2022 Corporate Update Conference Call Scheduled for 8:00 am ET Today BLACKSBURG, Va., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a clin

      11/15/21 7:30:00 AM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Landos Biopharma to Host Corporate Update Call

      BLACKSBURG, Va., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma Inc. (NASDAQ:LABP) today announced that it will report third quarter 2021 financial results and host a conference call to provide a corporate update on November 15, 2021. Following the release of the financial results, Landos will host a live webcast at 8:00 am ET. The webcast can be accessed through the Company's investor relations website at https://ir.landosbiopharma.com/, or by dialing 1-877-317-6789 (Toll Free) or 1-412-317-6789 (International) and asking to join the Landos Corporate Update call. The webcast will be archived and be available for replay on the Company's investor relations website. About Landos Biopha

      11/11/21 4:05:00 PM ET
      $LABP
      Biotechnology: Pharmaceutical Preparations
      Health Care